P/E ratio for Avidity Biosciences (RNA)

P/E ratio history for Avidity Biosciences from 2020 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
PTC Therapeutics PTCT	-5.71	-41.89%	🇺🇸 USA
Acorda Therapeutics ACOR	-0.0676	-99.31%	🇺🇸 USA
Sarepta Therapeutics SRPT	-7.72	-21.38%	🇺🇸 USA
Catalyst Pharmaceuticals CPRX	21.2	-315.74%	🇺🇸 USA
Fate Therapeutics FATE	-0.5991	-93.90%	🇺🇸 USA
Acceleron Pharma XLRN	N/A	N/A	🇺🇸 USA
Pfizer PFE	12.3	-225.42%	🇺🇸 USA
GlaxoSmithKline GSK	10.7	-208.53%	🇬🇧 UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.